# To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

> **NCT00768105** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** AZD1656
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00768105
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768105, "To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00768105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*